These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 20825984

  • 1. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Angelucci A, Mari M, Millimaggi D, Giusti I, Carta G, Bologna M, Dolo V.
    Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC, Parsons SJ.
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [Abstract] [Full Text] [Related]

  • 3. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
    Dietrich CS, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, Zimmer SG.
    Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR, Zimmer SG, Modesitt SC.
    Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
    Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC.
    Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
    [Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.
    Chobanian NH, Greenberg VL, Gass JM, Desimone CP, Van Nagell JR, Zimmer SG.
    Anticancer Res; 2004 Jan; 24(2B):539-45. PubMed ID: 15160991
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
    Fang Y, Hu Y, Wu P, Wang B, Tian Y, Xia X, Zhang Q, Chen T, Jiang X, Ma Q, Xu G, Wang S, Zhou J, Ma D, Meng L.
    Cancer Invest; 2011 May; 29(4):247-52. PubMed ID: 21345073
    [Abstract] [Full Text] [Related]

  • 13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [Abstract] [Full Text] [Related]

  • 14. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.
    Clin Cancer Res; 2007 Feb 01; 13(3):1045-52. PubMed ID: 17289901
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L, Davis R, Anwar A, Behbakht K.
    Gynecol Oncol; 2008 Sep 01; 110(3):425-31. PubMed ID: 18619662
    [Abstract] [Full Text] [Related]

  • 17. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
    Shi W, Han X, Yao J, Yang J, Shi Y.
    Leuk Res; 2012 Jun 01; 36(6):749-55. PubMed ID: 22475365
    [Abstract] [Full Text] [Related]

  • 18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D.
    Int J Oncol; 2007 Sep 01; 31(3):633-41. PubMed ID: 17671692
    [Abstract] [Full Text] [Related]

  • 19. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Nidhyanandan S, Thippeswamy BS, Chandrasekhar KB, Reddy ND, Kulkarni NM, Karthikeyan K, Khan FR, Raghul J, Vijaykanth G, Narayanan S.
    Anticancer Drugs; 2017 Oct 01; 28(9):1002-1017. PubMed ID: 28727579
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.